BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33965974)

  • 1. Clinical significance of CCNE1 copy number gain in acral melanoma patients.
    Wu X; Yan J; Yu J; Cheng Z; Guo Q; Kong Y; Guo J
    Melanoma Res; 2021 Aug; 31(4):352-357. PubMed ID: 33965974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.
    Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J
    Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker Assessment of HR Deficiency, Tumor
    Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
    Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

  • 7. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
    Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
    J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    Moon KR; Choi YD; Kim JM; Jin S; Shin MH; Shim HJ; Lee JB; Yun SJ
    J Invest Dermatol; 2018 Apr; 138(4):933-945. PubMed ID: 29191620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased
    Yan J; Yu J; Wu X; Xu T; Yu H; Dai J; Ma M; Tang H; Xu L; Chi Z; Si L; Sheng X; Cui C; Kong Y; Guo J
    J Cancer; 2018; 9(7):1267-1276. PubMed ID: 29675108
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
    Haugh AM; Zhang B; Quan VL; Garfield EM; Bubley JA; Kudalkar E; Verzi AE; Walton K; VandenBoom T; Merkel EA; Lee CY; Tan T; Isales MC; Kong BY; Wenzel AT; Bunick CG; Choi J; Sosman J; Gerami P
    J Invest Dermatol; 2018 Feb; 138(2):384-393. PubMed ID: 28870692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
    Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
    J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
    Nathanson KL; Martin AM; Wubbenhorst B; Greshock J; Letrero R; D'Andrea K; O'Day S; Infante JR; Falchook GS; Arkenau HT; Millward M; Brown MP; Pavlick A; Davies MA; Ma B; Gagnon R; Curtis M; Lebowitz PF; Kefford R; Long GV
    Clin Cancer Res; 2013 Sep; 19(17):4868-78. PubMed ID: 23833299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAB2 amplifications refine molecular classification of melanoma.
    Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
    Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations in primary melanoma in Taiwan.
    Sheen YS; Tan KT; Tse KP; Liao YH; Lin MH; Chen JS; Liau JY; Tseng YJ; Lee CH; Hong CH; Liao JB; Chang HT; Chu CY
    Br J Dermatol; 2020 May; 182(5):1205-1213. PubMed ID: 31408190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.
    Yu J; Yu J; Wu X; Guo Q; Yin T; Cheng Z; Dai J; Kong Y; Guo J
    Clin Sci (Lond); 2020 Jan; 134(2):193-205. PubMed ID: 31919521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.
    Yan J; Wu X; Yu J; Yu H; Xu T; Brown KM; Bai X; Dai J; Ma M; Tang H; Si L; Chi Z; Sheng X; Cui C; Kong Y; Guo J
    Eur J Cancer; 2018 Jan; 89():90-101. PubMed ID: 29245078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.
    Pils D; Bachmayr-Heyda A; Auer K; Svoboda M; Auner V; Hager G; Obermayr E; Reiner A; Reinthaller A; Speiser P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Berger A; Cacsire Castillo-Tong D; Zeillinger R
    Eur J Cancer; 2014 Jan; 50(1):99-110. PubMed ID: 24176298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
    Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
    APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.